Effect of Reversible Intermittent Intra-abdominal Vagal Nerve Blockade on Morbid Obesity: The ReCharge Randomized Clinical Trial
Ikramuddin S, Blackstone RP, Brancatisano A, Toouli J, Shah SN, Wolfe BM, Fujioka K, Maher JW, Swain J, Que FG, Morton JM, Leslie DB, Brancatisano R, Kow L, O’Rourke R, Deveney C, Takata M, Miller CJ, Knudson MB, Tweden KS, Shikora SA, Sarr MG, Billington CJ. Effect of Reversible Intermittent Intra-abdominal Vagal Nerve Blockade on Morbid Obesity: The ReCharge Randomized Clinical Trial. JAMA 2014, 312: 915-922. PMID: 25182100, DOI: 10.1001/jama.2014.10540.Peer-Reviewed Original ResearchConceptsExcess weight lossNerve block groupPrimary safety objectiveWeight lossMorbid obesityAdverse eventsSham groupClinical trialsEfficacy objectiveMean percentage excess weight lossBlock groupPercentage excess weight lossSerious adverse event ratesSham-controlled clinical trialSham device groupVagal nerve blockadeWeight management educationSerious adverse eventsBariatric surgery resultsLong-term morbidityAdverse event ratesObesity-related conditionsNerve block therapyBody mass indexAbdominal pain